AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2025

Jun 9, 2025

6965_dirs_2025-06-09_b99fb800-3dbd-47d2-b7ca-324fb9b2317c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-06-05

Reporting Person: Aghion Daniel (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-05	Common Stock	A	30000	—	Acquired	68820	Direct
2025-06-05	Common Stock	A	8371	—	Acquired	77191	Direct

Footnotes

F1: . Represents Restricted Stock Units ("RSUs") that will vest in equal portions of 10,000 as follows: January 1, 2026, January 1, 2027 and January 1, 2028. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

F2: Represents RSUs that will vest in equal installments as follows: on grant, July 1, 2025, October 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.